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Decreased level of reduced glutathione (GSH) were found in CF epithelial lining ﬂuid
and anecdotal evidence suggested improved lung function after GSH-inhalation. In a
double-blind, placebo-controlled, randomized clinical trial we investigated the safety
and efﬁcacy of inhaled glutathione.
Of 153 subjects (age 8 years, FEV1 40%, 90%) 73 inhaled glutathione (646mg
GSH-Na) over 24 wks via a specialized e-ﬂow device twice daily and 80 used placebo
(0.9% saline). A 5% increase in lung function compared to placebo was predeﬁned as
clinically relevant.
The primary outcome variable, the absolute change in FEV1 was not signiﬁcantly
affected by treatment over the study period. Exploratory analysis showed only a small
effect on FEV1 at 3 months of treatment. Body weight, rate and time to pulmonary
exacerbations, quality of life (QOL) total and respiratory score were not different.
Safety was good, with no differences of adverse events, rate of premature withdrawals
and change in laboratory parameters between treatment groups. In the GSH-group,
both free and total GSH in sputum samples were increased after 3 and 6 months
of treatment, however, cellular, inﬂammatory, redox-state and proteolytic markers
remained unchanged.
This study did not demonstrate a statistically signiﬁcant effect of inhaled GSH on
the primary endpoint FEV1. Other important secondary endpoints also did not change
signiﬁcantly with treatment. Inhaled glutathione was save at dose and duration applied.
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Introduction: PEs in CF are linked to accelerated declines in lung function and
mortality [1]. Two large phase III trials of inhaled dry powder mannitol (IDPM)
have demonstrated sustained, clinically meaningful improvements in lung function
from baseline over 26 weeks. The large population from these studies provides the
opportunity to explore the impact of IDPM on PEs in CF.
Methods: Data were pooled from two similar, randomized (3:2), controlled, parallel
group phase III studies in which a total of 600 pts received either IDPM (400mg)
or control (mannitol 50mg) b.i.d. for 26 weeks. Protocol deﬁned pulmonary
exacerbations (PDPE) were assessed using Fuchs’ criteria [2].
Results: The incidence of pts with 1 PDPE was 29% lower (p = 0.039) in the
IDPM group than in the control group. Associated rescue antibiotic use incidence
was reduced by 30% (p = 0.033), in the IDPM group vs. the control. The supportive
positive trend of a 22% reduction in PDPE-related hospitalization incidence did not
reach statistical signiﬁcance (p = 0.219). The annualized PDPE rate was signiﬁcantly
lower in those patients treated with IDPM who had any improvement from baseline
over 26 weeks in %-predicted FEV1 (0.56 PDPE/year) compared to those who did
not show FEV1 improvement (1.36/year) (p = 0.03).
Conclusions: PEs are a key driver of worsening lung function in CF, which is not
restored to pre-exacerbation levels in up to 25% of cases. IDPM has an important
impact on the rate of PEs, with a reduced risk seen predominantly in those patients
who had also shown an improvement in pulmonary function.
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Objectives: Ciproﬂoxacin (CIP) is used to treat CF patients and is partly
metabolised in the liver by the CYP3A4 enzyme. We investigated the correlation
between the enzyme activity and the metabolism of CIP. A Monte Carlo simulation
was performed to predict eventual treatment failure.
Methods: We included 22 CF patients (21−53 yr) with chronic P. aeruginosa lung
infections. The CYP3A activity was measured using the ERMBT. 500mg CIP was
given orally and blood samples were collected every half hour the ﬁrst 3 h and at
6 and 12 h. The concentrations of CIP were calculated by using a biological assay.
AUC, Tmax and Cmax were calculated. The Monte Carlo simulation was based on
the MIC of 119 P. aeruginosa strains.
Results: A 14-fold variation, median (range), in AUC (mg·min/liter); 473.5 (138–
1880) for CIP, a 30-fold variation in Cmax (mg/liter); 2 (0.25−7.6) and a 3 fold-
variation in Tmax (min); 91 (46–153) was found.
We found an 8-fold variation in the CYP3A4 activity, with a median (range) of 0.8
(0.3−2.0), but no correlation with CIP metabolism was found.
The Monte Carlo simulation showed that some of the patients did not reach
concentrations high enough to eradicate the bacteria.
Conclusion:We found a large variation in the metabolism of CIP and some patients
may not have reached a high enough MIC/AUC ratio. We therefore recommend
that plasma concentrations and MIC of the bacteria are measured regularly to avoid
treatment failure.
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Objectives: A randomized placebo (PBO)-controlled blinded 2-part trial of AZLI
was conducted at 35 sites in the US and Canada. In the 24 wk randomized phase,
there was no difference between patients (pts) treated with AZLI or PBO in %
change in FEV1% predicted, measured by the time-adjusted area under the curve
(AUCave). Results of the 24 wk single-arm open label (OL) AZLI phase are
presented.
Methods: CF pts 6 yrs with chronic Burk infection and stable pulmonary disease
were randomized to receive 24 wks of AZLI 75mg or PBO TID daily via the Pari
Investigational eFlow® Nebuliser, followed by 24 wks of OL AZLI.
Results: Of 100 pts randomized, 84 pts (39 AZLI; 45, PBO) continued in the OL
phase [mean age 26.6 yrs; mean FEV1 56% predicted (range 16%-105%)]. Lung
function results are shown in Table 1. The number of respiratory events requiring
antibiotics decreased in PBO pts when switched to AZLI (73 to 64). Total adverse
event rates were similar in both groups.
Mean Relative Change in FEV1% Predicted
Treatment Mean Change from Day 0 (Rand) Mean Change from Week 24 (OL)
(Rand/OL) Day 28 Wk 24 AUCave at
Wk 24
Wk 28 Wk 48 AUCave at
Wk 48
AZLI/AZLI 4.35 1.69 0.16 −2.43 −2.92 −1.52
PBO/AZLI −0.28 −2.92 −0.75 6.15 0.34 2.29
Conclusions: Continuous AZLI treatment was safe in Burk-infected CF pts and
maintained FEV1 above baseline for the ﬁrst 24 wks of AZLI treatment in both
AZLI-randomized pts and PBO pts crossing over to AZLI.
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